Deep vein thrombosis treatment approach: Difference between revisions
/* ACCP 2012 Guidelines: Recommendations for initial approach in patients with acute DVT of the leg (DO NOT EDIT){{cite journal |author=Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ |title=Executive summary: Antithrombotic Therapy a... |
|||
| Line 3: | Line 3: | ||
{{Deep vein thrombosis}} | {{Deep vein thrombosis}} | ||
==Treatment | ==Treatment Approach== | ||
The following algorithm describes the treatment approach to [[DVT]]<ref name="pmid22315257">{{cite journal |author=Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ |title=Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines|journal=Chest |volume=141 |issue=2 Suppl |pages=7S–47S |year=2012 |month=February |pmid=22315257 |doi=10.1378/chest.1412S3 |url=}}</ref>: | The following algorithm describes the treatment approach to [[DVT]]<ref name="pmid22315257">{{cite journal |author=Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ |title=Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines|journal=Chest |volume=141 |issue=2 Suppl |pages=7S–47S |year=2012 |month=February |pmid=22315257 |doi=10.1378/chest.1412S3 |url=}}</ref>: | ||
Revision as of 17:08, 31 January 2013
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] ; Kashish Goel, M.D.; Assistant Editor(s)-In-Chief: Justine Cadet
|
Deep Vein Thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Deep vein thrombosis treatment approach On the Web |
|
Risk calculators and risk factors for Deep vein thrombosis treatment approach |
Treatment Approach
The following algorithm describes the treatment approach to DVT[1]:
#Administer parenteral anticoagulants as per ACCP guidelines using the recommended doses.
¶Comorbid conditions may include history of hemorrhagic CVA, recent bleeding episodes, recent surgery or trauma, severe uncontrolled hypertension, renal failure, potential for non-compliance, suspicion of PE or pregnancy.
ACCP 2012 Guidelines: Recommendations for initial approach in patients with acute DVT of the leg (DO NOT EDIT)[1]
| Grade 1 |
| "1. In patients with acute DVT of the leg treated with vitamin K antagonist (VKA) therapy, we recommend initial treatment with parenteral anticoagulation (low-molecular-weight heparin [LMWH], fondaparinux, IV unfractionated heparin [UFH], or subcutaneous [SC] UFH) over no such initial treatment. (Level of evidence B)" |
| Grade 2 |
| "1. In patients with a high clinical suspicion of acute VTE, we suggest treatment with parenteral anticoagulants compared with no treatment while awaiting the results of diagnostic tests. (Level of evidence C)" |
| "2. In patients with an intermediate clinical suspicion of acute VTE, we suggest treatment with parenteral anticoagulants compared with no treatment if the results of diagnostic tests are expected to be delayed for more than 4 h (Level of evidence C)." |
| "3. In patients with a low clinical suspicion of acute VTE, we suggest not treating with parenteral anticoagulants while awaiting the results of diagnostic tests, provided test results are expected within 24 h (Level of evidence C)." |
References
- ↑ 1.0 1.1 Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ (2012). "Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): 7S–47S. doi:10.1378/chest.1412S3. PMID 22315257. Unknown parameter
|month=ignored (help)